Gemcitabine: current role and future options in the treatment of ovarian cancer

被引：17

作者：

Fruscella, E ^{[1
]}

Gallo, D ^{[1
]}

Ferrandina, G ^{[1
]}

D'Agostino, G ^{[1
]}

Scambia, G ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dept Gynecol Oncol, I-00168 Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2003年 / 48卷 / 01期

关键词：

gemcitabine; ovarian cancer; chemotherapy;

D O I：

10.1016/S1040-8428(03)00119-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancer is the gynecological malignancy with the highest mortality. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Despite improvements in outcome via carboplatin/paclitaxel based chemotherapy, 30% of patients with ovarian cancer fail to respond to primary therapy; moreover, 55-75% of responders relapse within I or 2 years from the end of primary treatment and die of the disease within 5 years from their initial diagnosis. Gemcitabine has been shown to be active as a single agent and in combination with other drugs, including carboplatin and paclitaxel, in the treatment of patients with recurrent ovarian cancer. It is currently under evaluation in new combinations for initial therapy in ovarian cancer patients. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

引用

页码：81 / 88

页数：8